Chemotherapy News and Research

Latest Chemotherapy News and Research

Calistoga to feature data on CAL-101 inhibitor for hematologic malignancies at ASH Annual Meeting

Calistoga Pharmaceuticals, Inc., the leader in the development of delta-isoform-selective phosphatidylinositol 3-kinase (PI3K-delta) inhibitors for the treatment of cancer and inflammatory diseases, today announced the upcoming presentation of clinical and preclinical results supporting the clinical benefit of CAL-101, an oral, PI3K-delta inhibitor, in the treatment of patients with hematologic malignancies.

30 Nov 2010

Hana Biosciences to present Marqibo data for acute lymphoblastic leukemia at ASH Annual Meeting

Hana Biosciences, a biopharmaceutical company focused on strengthening the foundation of cancer care, today announced that data regarding Marqibo for treatment of adults with relapsed/refractory acute lymphoblastic leukemia (ALL) will be the subject of two presentations at the 2010 Annual Meeting and Exposition of the American Society of Hematology (ASH) being held in Orlando, Florida from December 4-7, 2010.

30 Nov 2010

FDA approves Merit's phase 3 clinical trial protocol to treat primary liver cancer with QuadraSphere Microspheres

The Food and Drug Administration (FDA) has approved Merit Medical Systems, Inc.'s phase 3 clinical trial protocol to treat primary liver cancer with QuadraSphere™ Microspheres (hqTACE) for delivery of doxorubicin. The clinical trial will involve U.S. and international interventional radiologists who treat patients with localized, unresectable hepatocellular carcinoma (HCC), the most common form of liver cancer.

29 Nov 2010

Positive results from Oncolytics' combination REOLYSIN-docetaxel Phase I trial in advanced cancer

Oncolytics Biotech Inc. announced today that a paper entitled "REO-10: A Phase I Study of Intravenous Reovirus and Docetaxel in Patients with Advanced Cancer," was recently published by Comins et al in the journal Clinical Cancer Research (Clin Cancer Res 16(22):5564-5572).

29 Nov 2010

Texas Breast Specialists expands breast cancer treatment services

Texas Breast Specialists, part of Texas Oncology, has expanded its breast cancer treatment services in Dallas, McKinney, Bedford, Carrollton, and Plano, Texas to include the mobile Naviscan PEM scanner.

29 Nov 2010

JAK3 pathway highlighted as leukemia target

An intriguing study published in Expert Review of Anticancer Therapy has revealed that the signaling protein JAK3 represents a viable target in the treatment of a broad range of B-lineage cancers, including acute lymphoblastic leukemia (ALL).

28 Nov 2010

Collective efforts in transplantation reduces risk of treatment-related complications in blood cancer

A decade of refinements in marrow and stem cell transplantation to treat blood cancers significantly reduced the risk of treatment-related complications and death, according to an institutional self-analysis of transplant-patient outcomes conducted at Fred Hutchinson Cancer Research Center.

25 Nov 2010

Public health: Frequency of dialysis treatment questioned, chemotherapy drug shortages

A new study funded by the National Institutes of Health suggests that receiving dialysis six days a week results in better self-reported patient health than the conventional treatment of three times per week.

25 Nov 2010

Advaxis initiates ADXS11-001 clinical trial for cervix cancer

Advaxis, Inc., the live, attenuated Listeria monocytogenes (Listeria) immunotherapy company, has begun dosing patients in its 110 patient clinical trial of ADXS11-001 for the treatment of cervix cancer in women for whom cytotoxic treatment has failed.

24 Nov 2010

A new treatment landscape for triple-negative breast cancer

A concerted R&D effort directed at triple-negative breast cancer patients promises new treatment options in the near future, according to latest research from independent market analyst, Datamonitor.

24 Nov 2010

BioAlliance presents AMEP preclinical, phase I clinical results for melanoma at Electrochemotherapy Meeting

BioAlliance Pharma SA, a company dedicated to the supportive care and treatment of cancer patients, presented preclinical and promising preliminary phase I clinical results with its AMEP biotherapy at the "Electrochemotherapy 1st International Users' Meeting"(Bologna, Italy, November 19-20, 2010).

23 Nov 2010

Racial disparities in risk and survival among children with neuroblastoma: Study

Black, Asian, and Native American children are more likely than white and Hispanic children to die after being treated for neuroblastoma, according to new research on the pediatric cancer. The study, of more than 3,500 patients with the disease, is the largest ever to look at racial disparities in risk and survival for the most common solid cancer found in young children.

23 Nov 2010

Erbitux development program featured in ASCO's Clinical Cancer Advances report for third consecutive year

For the third year in a row, the American Society of Clinical Oncology (ASCO) has included Erbitux® (cetuximab) research in its annual report, Clinical Cancer Advances, which features the most significant studies of 2010. The report cites as a notable advance this year the finding that BRAF mutation status is a prognostic, not predictive, marker for Erbitux efficacy in metastatic colorectal cancer (mCRC).

23 Nov 2010

Ontario Cancer Plan third edition to address growing needs

The third edition of the Ontario Cancer Plan (OCP) ensures our cancer system serves the changing and growing needs of Ontarians. The Cancer Plan outlines priorities for cancer services, sets a course to transform cancer services from the patient perspective, and is driven by a commitment to quality across the cancer journey - from prevention to survivorship or palliative care - as the most effective way to manage cancer.

23 Nov 2010

Researchers identify trigger mechanism for quality control checkpoint in cell division process

Researchers from Huntsman Cancer Institute (HCI) at the University of Utah report that they have identified a previously undiscovered trigger mechanism for a quality control checkpoint at the very end of the cell division process in a paper to be published in the November 29 issue of The Journal of Cell Biology and online today.

23 Nov 2010

Largest genomic study of human medulloblastomas

Medulloblastomas are the most common malignant brain tumors of childhood, with 40 to 50 percent overall mortality. One of the greatest challenges in treating them is that they vary substantially from patient to patient. In the largest genomic study of human medulloblastomas to date, researchers from Children's Hospital Boston, together with collaborators, have identified six subtypes with distinct molecular "fingerprints" that will improve doctors' ability to direct and individualize treatment.

23 Nov 2010

Apricus files protocol of PrevOnco Phase 3 clinical trial for FDA SPA program

Apricus Biosciences, Inc., today announced that it has filed the protocol for a proposed Phase 3 clinical trial of PrevOnco, its proprietary treatment for hepatocellular carcinoma (liver cancer), with the U.S. Food and Drug Administration (FDA).

23 Nov 2010

Asbestos awareness important to prevent related cancer: Experts

Experts from Perth speculate Western Australia is yet to see the peak of asbestos-induced cancer, with renovators still failing to take proper precautions. According to director of the National Centre for Asbestos Related Diseases, Bruce Robinson, the next and third wave of mesothelioma patients would come out of those putting themselves and others at risk while taking on DIY home renovation projects.

22 Nov 2010

Cell Therapeutics announces preliminary results of phase II OPAXIO study for high-grade gliomas

Cell Therapeutics, Inc. announced the preliminary results of a phase II study of paclitaxel poliglumex (OPAXIO) combined with temozolomide (TMZ) and radiotherapy (RT) in patients with newly diagnosed high-grade gliomas.

22 Nov 2010

Celldex presents ACT III Phase 2 clinical trial data for glioblastoma multiforme at SNO Meeting

Celldex Therapeutics, Inc., today announced the presentation of complete data for the primary endpoint of ACT III, a multi-center, single arm, Phase 2 clinical trial of rindopepimut (CDX-110) in patients with newly diagnosed glioblastoma multiforme (GBM).

21 Nov 2010

Chemotherapy News and Research

Latest Chemotherapy News and Research

Calistoga to feature data on CAL-101 inhibitor for hematologic malignancies at ASH Annual Meeting

Hana Biosciences to present Marqibo data for acute lymphoblastic leukemia at ASH Annual Meeting

FDA approves Merit's phase 3 clinical trial protocol to treat primary liver cancer with QuadraSphere Microspheres

Positive results from Oncolytics' combination REOLYSIN-docetaxel Phase I trial in advanced cancer

Texas Breast Specialists expands breast cancer treatment services

JAK3 pathway highlighted as leukemia target

Collective efforts in transplantation reduces risk of treatment-related complications in blood cancer

Public health: Frequency of dialysis treatment questioned, chemotherapy drug shortages

Advaxis initiates ADXS11-001 clinical trial for cervix cancer

A new treatment landscape for triple-negative breast cancer

BioAlliance presents AMEP preclinical, phase I clinical results for melanoma at Electrochemotherapy Meeting

Racial disparities in risk and survival among children with neuroblastoma: Study

Erbitux development program featured in ASCO's Clinical Cancer Advances report for third consecutive year

Ontario Cancer Plan third edition to address growing needs

Researchers identify trigger mechanism for quality control checkpoint in cell division process

Largest genomic study of human medulloblastomas

Apricus files protocol of PrevOnco Phase 3 clinical trial for FDA SPA program

Asbestos awareness important to prevent related cancer: Experts

Cell Therapeutics announces preliminary results of phase II OPAXIO study for high-grade gliomas

Celldex presents ACT III Phase 2 clinical trial data for glioblastoma multiforme at SNO Meeting

Cancer Research - Second Edition eBook

Small solutions for big problems in drug discovery and delivery

Professor Nancy Ip: Pioneering New Paths in Neurodegenerative Therapy

Utilizing process Raman in optimizing cultivated meat production

Chemotherapy News and Research

Latest Chemotherapy News and Research

Cancer Research - Second Edition eBook

Small solutions for big problems in drug discovery and delivery

Professor Nancy Ip: Pioneering New Paths in Neurodegenerative Therapy

Utilizing process Raman in optimizing cultivated meat production

Newsletters you may be interested in